Morphinan-3,6,14-Triol, 4,5-Epoxy-17-(2-Propenyl)-, (5.Alpha.,6.Beta.)-
Opioid-Induced Constipation
S.L.A. Pharma AGSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Opioid-Induced Constipation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naldemedine BioDelivery Sciences International | Phase 3 | BBB |
Methylnaltrexone Bausch Health Americas, Inc. | Phase 3 | B |
Prucalopride Shire | Phase 3 | B |
Rdc-1036 Alkermes, Inc. | Phase 2 | B |
Linaclotide Forest Laboratories | Phase 2 | B |
View all 10 →
Same molecule, other indications
Morphinan-3,6,14-Triol, 4,5-Epoxy-17-(2-Propenyl)-, (5.Alpha.,6.Beta.)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →